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Background: Tumor necrosis factor (TNF) inhibition is central to the
therapy of inflammatory bowel diseases (IBD). However, the durability
and efficacy of this blockade hasn't been well studied and a better
understanding is crucial for the prognosis of long-term treatment and
decision making in case of loss of response (LOR) to these costly drugs.
Methods: Consecutive IBD Patients receiving anti-TNF agents from
Inselspital were identified and followed prospectively. Patient whole
blood was stimulated with a dose-titration of either human TNF or the
TLR agonist lipopolysaccharide (LPS) followed by flow cytometry.
Median fluorescence intensity of CD62L on the surface of granulocytes.
The change in EC50 (the concentration of TNF required to induce a 50%
shedding of surface CD62L) following the anti-TNF agent, was used to
predict the in vivo response, which was then correlated to the clinical
evolution to analyze the ability of this test to identify LOR to Anti-TNFs.
Results: We collected prospective clinical data and 2 blood samples,
before and after anti-TNF agent, on 33 IBD patients, 25 Crohn's disease
and 8 ulcerative colitis patients (45% females) between mid-2012 and
end 2013. The assay showed a functional blockade of TNF (PFR) for 22
patients (17 CD and 5 UC) whereas 11 (8 CD and 3 UC) had no
functional response (NR) to TNF blockade. Clinical characteristics (e.g.
diagnosis, disease location, smoking status and BMI) as well as #
infusions were not significantly different between predicted PFR and NR.
Among the 22 patients with PRF, only 1 patient was a clinical non
responders (LOR to anti-TNF), based on clinical prospective evaluation
by IBD gastroenterologists (PJ, FS and AM), and among the 11
predicted NR, 3 had no clinical LOR. Sensitivity of this test was 95% and
specificity 73% and AUC adjusted for age and gender was 0.81. During
follow up (median 10 months, range 3-15) 8 “hard” outcomes occurred (3
medic. flares, 4 resections and 1 new fistula) 2 in the PFR and 6 in the
NR group (25% vs. 75%; p<0.01).
Conclusions: CD62L (L-Selectin) shedding is the first validated test of
functional blockade of TNF alpha in anti-TNF treated IBD Patients and
will be a useful tool to guide medical decision on the use of anti-TNF
agents. Studies with ATI and trough level of the drugs are ongoing.
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Background: We examined the influence of coinfection with HBV on
prevalence and severity of different types of steatosis (i.e. viral vs
metabolic) in chronic HCV.
Methods: We retrospectively assessed steatosis prevalence and
severity in chronic HBV/HCV coinfected patients with a liver biopsy at
time of coinfection. Exclusion criteria were excessive alcohol
consumption, type 2 diabetes and antiviral therapy at time of liver biopsy.
HCV-monoinfected controls were matched according to BMI, HCV
viremia and genotype.
Results: 78 HBV/HCV coinfected patients and 115 HCV controls were
included. Clinical characteristics of HBV/HCV coinfected patients were:
average age: 42 years, males: 68%, average BMI: 25.1 kg/m
2
, cirrhotic:
24%, genotype 3 HCV: 26%, undetectable HBV viremia: 31%. There was
no significant difference in steatosis prevalence between the HBV/HCV
coinfected group and the HCV group (42% vs 44%, p=0.40). When
including only HCV genotype 3 patients with BMI <25 kg/m
2
(n=12
coinfected HBV/HCV) there was no difference in steatosis distribution
and severity between coinfected and HCV monoinfected patients
(p=0.28).
Conclusions: Based on these preliminary findings it appears that HBV
is not affecting prevalence and intensity of steatosis in HBV/HCV
coinfected patients vs HCV monoinfected patients, even in the subgroup
of HCV genotype 3 patients with normal BMI.
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EUS-guided fine needle aspiration (EUS-FNA) in pancreatic
masses: a prospective randomized study comparing the
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Introduction EUS-FNA has become a standard in pancreatic
masses diagnosis. It can be performed with a 22G or a 25 G
needle. It remains unclear if the 25G have the same diagnostic
yield than the 22G. To evaluate it, we perform a prospective,
randomized, double-blind, non-inferiority study
Patients and methods Patients presenting with pancreatic
solid masses between July 2010 and June 2012 were included.
They underwent EUS-FNA using a 22G needle and 25G needle
during the same endoscopic session. Three passages without
stylet were performed with each needle. The 25G and 22G
needle sequence being randomized. Cytological preparations
included smear cytology, ThinPrep and Cell Block. Specimens
were analyzed for diagnosis, cellularity, amount of blood and
digestive contamination. Final diagnosis was based on cytology
report, surgical pathology if available, repeated diagnosis
imaging and clinical follow-up.
Results 37 patients were included. For 34 malignant pancreatic
neoplasms was the final diagnosis. Diagnostis yield of 25G and
22G needles were 85.3% (29 patients) and 88.2% (30 patients)
respectively (p>0.05). The quality of specimens was
comparable regarding cellularity, blood and digestive
contamination. No complication occurred.
Conclusion Our study demonstrates the non-inferiority of the
25G needle’s performance compared the 22G for the diagnosis
of pancreatic masses.
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Background
Perfusion impairment at the anastomotic site is one of the most
important risk factors for anastomotic leakage (AL). Visual
assessment of intestinal microperfusion during surgery has
been found to be inefficient to predict AL. Microperfusion
patterns during surgery are unknown and reliable intraoperative
assessment of intestinal microperfusion is not established yet.
Methods
Patients undergoing colorectal resection between July 2013
and March 2014 were recruited. Measurements using a Visible
Light Spectroscope (VLS) were conducted during colorectal
resection. Reference: at the caecum (M1) and proximal to
planned resection (M2). After mobilization: proximal (M3) and
distal (M4) to the planned resection. After anastomosis: 1-2cm
proximal (M5) and distal (M6) to the anastomosis.
Results
18 patients with median age of 70y (IQR 56; 79) were included.
Main operation was laparoscopic sigmoidectomy (n=9, 50%).
Median duration of VLS measurement was 2:09 min (IQR 1:30,
5:45). The following median (IQR) serosal StO
2
were observed:
M1: 67% (60; 70), M2: 66% (57; 68), M3: 71% (57; 76), M4:
68% (52; 74), M5: 70% (57; 75), M6: 69% (61; 76).
Conclusions
Intraoperative microperfusion patterns during colorectal
resection show individual differences with a trend of increasing
variability of StO
2
following mobilization and anastomosis.
However, more patients need to be included to correlate
serosal StO
2
levels with patient outcome and complications.
